Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)

    ... treated with lenalidomide in the MDS-004 clinical trial were retrospectively assessed for p53 expression by ... syndromes. This study is based on data from the MDS 004 trial (clinicaltrials.gov identifier: NCT00179621). ...

    Research Article last updated 07/20/2018 - 5:15pm.

  2. How we treat higher-risk myelodysplastic syndromes

    ... is less than 6 months, and consideration should be given to clinical trials. Higher-risk eligible patients should be offered consultation ... therapy, induction chemotherapy or a clinical trial should be considered to prevent disease progression, although the ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia , and a ... transplantation and participation on a clinical trial . Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia , and a ... transplantation, and participation on a clinical trial . Bone Marrow ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia and a ... therapy, transplantation and participation on a clinical trial . Am. J. Hematol. 87:692-701, 2012. © 2012 Wiley Periodicals, Inc. ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy

    ... erythropoiesis and chronic transfusion therapy. The clinical consequences of iron overload include cardiac and/or hepatic failure, ... of using ICT in MDS. The placebo -controlled TELESTO trial ( NCT00940602 ) is currently examining the use of deferasirox in MDS ...

    Research Article last updated 07/18/2018 - 8:41am.

  7. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... with >30% blasts have also been shown in a recent phase III trial. Oral administration of azacitidine may enhance patient convenience, ... oral azacitidine (CC-486) have shown biological activity, clinical responses, and tolerability in patients with MDS and AML. Extended ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia

    ... peripheral-blood lymphocytes and is preferred in other clinical circumstances. METHODS: From December 2005 through July 2010, we performed a randomized trial comparing these two ATG formulations in conventional regimens. Patients ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes.

    ... and the malignant clone . A recent Phase I trial testing the lenalidomide and azacitidine combination yielded encouraging ... addition of lenalidomide to azacitidine provides additional clinical benefit over azacitidine monotherapy. ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

    ... BACKGROUND: In the AZA-001 trial, azacitidine (75 mg/m(2)/d subcutaneously for Days 1-7 of every ... category in 48% of patients, and therefore may enhance clinical benefit in patients with higher-risk MDS. ...

    Research Article last updated 07/20/2018 - 5:14pm.